Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.55 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27515960 | 0.93 | ESR2 (0.52) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL28844152 | 0.93 | TRPM8 (0.56) | CA1CA2PARP10PARP1PARP2 | |
| Water SCHEMBL27597764 | 0.91 | TRPM8 (0.55) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL2239304 | 0.87 | CA2 (0.66) | CA1CA2CA12CA9 | |
| SCHEMBL22501255 | 0.86 | CA1 (0.53) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL1304250 | 0.84 | PPARA (0.51) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL27500838 | 0.82 | TRPM8 (0.43) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL7615944 | 0.82 | CA1 (0.53) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL28332018 | 0.81 | POLB (0.55) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL4601283 | 0.81 | CA1 (0.54) | CA1CA2PARP10PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150569-A1 | IMIDAZOTETRAZINE COMPOUNDS AND TREATMENT OF TMZ-RESISTANT CANCERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-110878035-B | Method for preparing symmetrical urea compound | 中国科学院化学研究所 | 2021-01-05 | — | — | CN | disclosed |
| CN-110878035-A | Method for preparing symmetrical urea compound | 中国科学院化学研究所 | 2020-03-13 | — | — | CN | disclosed |
| US-8476286-B2 | for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476286-B2 | for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476286-B2 | for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2191832-A1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-2191832-A1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-1401451-B1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-1401451-B1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-6541476-B1 | Treating multiple sclerosis or encephalomyelitis in a human | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | disclosed |
| US-6534509-B1 | Derivatives are useful as anti-inflammatory agents. This invention is also directed to pharmacetutical compostions for inflammation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-18 | — | — | US | disclosed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| WO-2002102782-A2 | QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE | NOVARTIS AG (CH) | 2002-12-27 | — | — | WO | disclosed |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGSCHELLSCHAFT | 2002-11-28 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| EP-0732338-B1 | 2,2-Difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides | LILLY CO ELI (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| EP-0732338-A1 | 2,2-Difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides | ELI LILLY AND COMPANY (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5521294-A | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides | ELI LILLY AND COMPANY (US) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | CA1 4558/4885CA2 2886/4885PARP10 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.